Vaccines against SARS-CoV-2 are likely to be critical in the management of the ongoing pandemic. A number of candidates are in Phase III human clinical trials, including ChAdOx1 nCoV-19 (AZD1222), a replication-deficient chimpanzee adenovirus-vectored vaccine candidate. In preclinical trials, the efficacy of ChAdOx1 nCoV-19 against SARS-CoV-2 challenge was evaluated in a ferret model of infection. Groups of ferrets received either prime-only or prime-boost administration of ChAdOx1 nCoV-19 via the intramuscular or intranasal route. All ChAdOx1 nCoV-19 administration combinations resulted in significant reductions in viral loads in nasal-wash and oral swab samples. No vaccine-associated adverse events were observed associated with the ChAdOx1 nCoV-19 candidate, with the data from this study suggesting it could be an effective and safe vaccine against COVID-19. Our study also indicates the potential for intranasal administration as a way to further improve the efficacy of this leading vaccine candidate.
【저자키워드】 viral infection, Vaccines, 【초록키워드】 COVID-19, SARS-CoV-2, Efficacy, Vaccine, pandemic, Infection, AZD1222, Viral load, ferret, management, adverse event, vaccine candidate, group, Critical, trials, intranasal, ChAdOx1 nCoV-19, intramuscular, Combination, administration, phase, Safe, candidate, human clinical trials, oral swab, effective, IMPROVE, evaluated, indicate, reductions in, ChAdOx1 nCoV-19 against, chimpanzee adenovirus-vectored vaccine, intranasal route, 【제목키워드】 SARS-CoV-2, AZD1222, ferret, vaccine candidate, ChAdOx1 nCoV-19, significantly, reduce,